Oral GLP-1 Pill Shows 12% Weight Loss — Colorado Trial Update

A new oral obesity drug just posted Phase 2b results that deserve attention — especially here in Colorado, where we see a lot of patients who struggle with daily injections.

The study: Aleniglipron (GSBR-1290), developed by Structure Therapeutics, achieved up to 12.1% weight loss at 36 weeks in a 230-participant randomized trial published in Nature Medicine. The highest dose (120 mg) drove the result; placebo subtracted about 2.5%. Robert Kushner, MD of Northwestern — a veteran of the semaglutide obesity trials — co-authored the paper.

Why this matters: Aleniglipron is a small-molecule GLP-1, not a peptide. That distinction matters. Peptide-based GLP-1s like semaglutide and tirzepatide require refrigeration and can’t be taken with certain foods. Aleniglipron is chemically synthesized, stable at room temperature, and has no food-restriction label. In practical terms, that’s a pill you take in the morning with or without breakfast — no special handling.

The oral GLP-1 race has several contenders. Pfizer’s danuglipron was largely shelved over liver safety. AstraZeneca’s elecoglipron is in development. Eli Lilly’s orforglipron posted similar Phase 2 numbers (~10-12% at 36 weeks). Structure is now the most advanced small-molecule entrant with a clear Phase 3 path.

What this means clinically: We’re not there yet. Phase 2b is a mid-stage signal, not an approval. But the 12% figure at 36 weeks in a relatively small trial is consistent with — though not directly comparable to — what we saw emerge from early semaglutide and tirzepatide studies. The safety and durability data from Phase 3 will matter.

The Colorado angle: Colorado’s high altitude and dry climate affect hydration and, theoretically, drug absorption — a real consideration for anyone on daily medications. An oral GLP-1 with no food restrictions and no cold-chain requirement is particularly relevant for Coloradans who travel, work irregular hours, or spend time at elevation. The University of Colorado School of Medicine is also actively involved in obesity trial recruitment, which means local patients may have earlier access to Phase 3 programs.

Phase 3 is expected to begin in the second half of 2026. We’ll be watching.

Research Brief | Dr. Ethan Lazarus, MD | Clinical Nutrition Center | August 13, 2026